Mar 18 |
Pharvaris Announces Phase 3 Clinical Study Design for Recently Initiated RAPIDe-3 Study, and Presents Quality-of-Life Improvement and Caregiver Behavior Data at Two Recent HAE Congresses
|
Mar 6 |
Pharvaris to Present Deucrictibant Clinical Data at Upcoming Congresses
|
Mar 5 |
Pharvaris to Participate in the Leerink Global Biopharma Conference 2024
|
Feb 22 |
Positive Results from CHAPTER-1 Phase 2 Study of Deucrictibant for the Prophylactic Treatment of HAE Attacks to be Presented at AAAAI 2024 Annual Meeting
|
Feb 16 |
Pharvaris Announces Extraordinary Meeting of Shareholders
|
Jan 26 |
Pharvaris to Present at the WSAAI Annual Meeting 2024
|
Jan 23 |
Pharvaris (PHVS) Up as FDA Lifts Clinical Hold on HAE Program
|
Jan 22 |
Top-Notch Pharvaris Eyes Profit-Taking Zone On A Key FDA Decision
|
Jan 22 |
Pharvaris rises as FDA lifts hold on hereditary angioedema candidate
|
Jan 22 |
Pharvaris Announces FDA Lifting of the Clinical Hold of Deucrictibant for the Prophylactic Treatment of HAE Attacks
|